おすすめの製品
由来生物
mouse
品質水準
抗体製品の状態
purified antibody
抗体製品タイプ
primary antibodies
クローン
H11.H3, monoclonal
分子量
calculated mol wt 55.8 kDa
observed mol wt ~N/A kDa
精製方法
using protein G
化学種の反応性
virus
包装
antibody small pack of 100
テクニック
ELISA: suitable
neutralization: suitable
アイソタイプ
IgG2bκ
タンパク質IDアクセッション番号
UniProtアクセッション番号
保管温度
-10 to -25°C
特異性
Clone H11.H3 is a mouse monoclonal antibody that detects HPV11. It targets an epitope within the Major capsid protein L1.
免疫原
Intact HPV-11 virions obtained from morphologically transformed human foreskin xenografts grown subrenally in athymic mice.
アプリケーション
Quality Control Testing
Isotype testing: Identity Confirmation by Isotyping Test.
Isotyping Analysis: The identity of this monoclonal antibody is confirmed by isotyping test to be mouse IgG2b, kappa.
Tested Applications
Enzyme Immunoassay Analysis: A representative lot of this antibody detected HPV11 protein in ELISA application.
Neutralizing: A representative lot of this antibody neutralized HPV11 in neutralizing application (Christensen, N.D., et al. (1994). Virology. 205(1):329-35; Christensen, N.D., et al. (1996). Virology. 224(2):477-86).
ELISA Analysis: A representative lot of this antibody detected HPV11 protein in ELISA application (Christensen, N.D., et al. (1990). J Virol. 64(11):5678-81; Christensen, N.D., et al. (1994). Virology. 205(1):329-35 ; Christensen, N.D., et al. (1996). Virology. 224(2):477-86; Panicker, G., et al. (2021). J Immunol Methods. 498:113136; Jerajani, K., et al. (2022). J Pharm Sci. 111(11):2983-2997).
Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.
Isotype testing: Identity Confirmation by Isotyping Test.
Isotyping Analysis: The identity of this monoclonal antibody is confirmed by isotyping test to be mouse IgG2b, kappa.
Tested Applications
Enzyme Immunoassay Analysis: A representative lot of this antibody detected HPV11 protein in ELISA application.
Neutralizing: A representative lot of this antibody neutralized HPV11 in neutralizing application (Christensen, N.D., et al. (1994). Virology. 205(1):329-35; Christensen, N.D., et al. (1996). Virology. 224(2):477-86).
ELISA Analysis: A representative lot of this antibody detected HPV11 protein in ELISA application (Christensen, N.D., et al. (1990). J Virol. 64(11):5678-81; Christensen, N.D., et al. (1994). Virology. 205(1):329-35 ; Christensen, N.D., et al. (1996). Virology. 224(2):477-86; Panicker, G., et al. (2021). J Immunol Methods. 498:113136; Jerajani, K., et al. (2022). J Pharm Sci. 111(11):2983-2997).
Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.
ターゲットの説明
Major capsid protein L1 (UniProt: P04012) is encoded by the L1 gene in Human papillomavirus 11. The Major Capsid Protein L1 of Human papillomavirus is the primary structural protein responsible for the formation of the viral capsid, that encapsulates the genomic DNA together with Minor Capsid Protein L2. The viral capsid is composed of 360 copies of the L1 protein forming 72 pentamers, that assemble into the icosahedral capsid structure, while the L2 protein localizes along the inner surface of the virion and plays a role in capsid stabilization through interaction with the Major Capsid Protein L1. The L1 protein facilitates the attachment of the virus to the host cell by interacting with heparan sulfate proteoglycans on the cell surface, a critical step for infection. Recombinantly expressed Major Capsid Protein L1 can spontaneously assemble into Virus Like-Particles (VLPs) and were used for the development of neutralizing antibodies that show high degree of Human papillomavirus type-specificity. Based on their oncogenic potential, Human papillomaviruses (HPVs) can be classified as low-risk HPV types, (e.g.: HPV6 and HPV11, the most common serotypes) which do not cause cancer but can lead to skin and genital warts, and high-risk HPV types (e.g.: HPV 16, 18, 31, 33, 35, 45, 52, 58), that are responsible for HPV related cancers. Vaccines targeting the L1 protein, have been developed and are effective in preventing infection with the most oncogenic HPV types by inducing a robust antibody response. (Ref.: Hareza, D. A., (2022) Int. J. Mol. Sci., 23, 1818.; Christensen, N.D., et al. (1990). J Virol. 64:11, 5678-81; Christensen, N.D., et al. (1996). Virology. 224(2):477-86; Brown, M.J., et al. (2014). Clin Vaccine Immunol. 21:4, 587-93)
物理的形状
Purified mouse monoclonal antibody IgG2b in PBS without preservatives.
再構成
1.0 mg/mL. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
保管および安定性
Store at -10°C to -25°C. Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
その他情報
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
免責事項
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our 製品選択ツール.
保管分類コード
12 - Non Combustible Liquids
WGK
WGK 2
引火点(°F)
Not applicable
引火点(℃)
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
Jan Code
MABF3208-25UG:
MABF3208-100UG:
試験成績書(COA)
製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら(テクニカルサービス)